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Abstract
In this case report we present an unusual appearance of myo-
cardial uptake of Tc-99m HDP in a 59-year-old renal transplant
patient who was imaged while looking for metastases from ade-
nocarcinoma of the prostate. Subsequent investigation demon-
strated no obvious cause for this appearance, such as myocar-
dial disease or metastatic cancer. The case report, therefore,
discusses the possible causes of such an appearance and re-
views the literature concerning this phenomenon.
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Case report
A 59-year-old patient was under investigation for prostate en-
largement. Histology confirmed adenocarcinoma of the prostate
with Gleeson score 3 + 3. Subsequent staging with MRI and bone
scintigraphy was undertaken. MRI showed the disease to be con-
fined to the prostate with no capsular involvement. Whole body
scintigraphy was performed after administration of 592 MBq of
Tc-99m-HDP. This showed uptake in the lower thoracic spine that
was subsequently found to be secondary to degenerative disease.
However, there was marked diffuse uptake of Tc-99m-HDP through-
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out the myocardium (Figure 1). Myocardial uptake was confirmed
by SPECT of the thorax (Figure 2). Repeat Bone scintigraphy with
Tc-99m HDP repeated after five months did not reveal any change.
The patient had previously received a renal transplant which had
some mild impairment with biochemical markers showing raised
urea and creatinine (11.6 mmol/l and 213 μmol/l, respectively). The
patient did not need renal replacement therapy. Other biochemi-
cal markers, except for the PSA, were unremarkable with a par-
Figure 1. Whole body image performed 3 hours after administration of
550 MBq Tc-99m HDP. There is uptake in the 6th thoracic vertebrae and
both shoulders, confirmed on radiology to be due to degenerative dis-
ease; however, there is also uptake in the left lower chest.
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athormone (PTH) 26.3 pmol/l, calcium 2.25 mmol/l, corrected cal-
cium 2.21 mmol/l, and PSA 4.3 μmol/l. A chest X-ray taken one
year prior to the first bone scan did not show any evidence of pul-
monary or myocardial calcification.  As part of his assessment for
renal transplantation, 12 months previously he had had a routine
myocardial perfusion scan which confirmed that this patient did
not have any objective evidence of ischaemic heart disease. The
patient did have a history of hypercholesterolaemia (baseline
7.7 mmol) and was started on 40 mg fluvastatin in 1997 and
changed to atorvastatin after 6 months to achieve better control.
From 1998 until the time of the bone scan, this patient’s atorvasta-
tin was increased from 20 mg to 60 mg daily.
Discussion
Diffuse Tc-99m-diphosphonate uptake into soft tissues such
as the heart muscle has been recognised in the absence of known
cardiac or other disorders has been documented and due to
deemed ‘benign’ myocardial uptake [1–3]. Tc-99m-diphospho-
nate uptake in the myocardium has also been associated with
hypercalcaemia, secondary hyperparathyroidism, radiation ther-
apy, adriamycin, and amyloidosis [4–9]. The aetiology has been
attributed to hypercalcaemia and altered plasma binding in some
of these conditions. Explanations for so-called ‘benign’ uptake
have also included atherosclerosis; however, studies have shown
there to be an association with this finding and prostate cancer
[10, 11]. This raises the possibility that both conditions may be
related to androgen related process. An association has been
found between adverse cardiac events following myocardial inf-
arction and raised PSA. It is postulated that Human kallikrein 2
(hK2) and other proteases involved in converting the precursor of
PSA (pro-PSA) to PSA may explain this finding [12]. It follows that
an intermediate metabolite may alter the form of the radiophar-
maceutical such that it would have greater soft tissue bone affin-
ity and accumulate in the myocardium. However, it is unclear why
there is isolated uptake in the myocardium, and whether this is
related to a metabolic process or intracellular deposits unique to
myocardial cells.
Myocardial uptake of Tc-99m MDP has been reported in a
patient with secondary hyperparathyroidism where uptake was
demonstrated in the abdominal aorta and iliac arteries in addi-
tion to the myocardium [13]. In a case of renal failure, progres-
sive uptake of the radiotracer was noted in the myocardium, kid-
neys, stomach, lungs, and skeletal muscles, which was in keep-
ing with CT evidence of microcalcification [14]. Similarly, system-
ic amyloidosis is also found in several visceral organs [15]. Isola-
ted uptake of Tc-99m diphosphonates in the myocardium is there-
fore not in keeping with the pattern of uptake in secondary hyper-
parathyroidism or amyloidosis.
Al-Nahhas and colleagues [11] reported a 2.3% prevalence of
Tc-99m HDP or MDP myocardial uptake of all bone scintigrams
performed in their department over a two-year period. The expe-
rience in this institution points to the fact that myocardial uptake in
bone scintigraphy is far less frequent, with this being the only case
seen in the last ten years, during which time over 1000 patients
with prostate cancer have been imaged. Furthermore, Al-Nahhas
et al. demonstrated the highest rate of this observation in male
patients over the age of 80, of which 76% also had prostate can-
cer. Conversely, 12.5% of all patients with prostate cancer under-
going bone scintigraphy were found to have myocardial uptake.
Interestingly, it was noted that 2.5% of patients with malignancies
other than prostate cancer also demonstrated myocardial uptake
but only in a cohort over 80 years of age.
An alternative theory may be related to the use of statins. The
patient in this case had been receiving statin therapy for over a de-
cade. Statins are associated with oxidation injury demonstrated by
in vivo elevation of isoprostanes [16]. Studies have demonstrated
the uptake of Tc-99 diphosphonates in skeletal muscle due to myo-
sitis/rhabdomyolysis secondary to statins; however, this effect has
not been demonstrated on the myocardium.
Figure 2. Tomographic images (displayed as transverse, sagittal, and coronal slices) of the left lower chest confirm the uptake is within the myocardium.
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Conclusion
Myocardial uptake of Tc-99m HDP is rarer than previously de-
scribed and has an association with prostate cancer. Further in-
vestigation of this observation may reveal the biochemical expla-
nation for the isolated myocardial uptake of the radiopharmaceuti-
cal and the link with prostate cancer.
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